Herceptin® is indicated for patients with (a) metastatic HER2‐overexpressing breast cancer either as a single agent or in combination with paclitaxel (b) metastatic HER2‐overexpressing gastric cancer in combination with cisplatin and capecitabine/5‐fluorouracil and (c) HER2‐overexpressing breast cancer as an adjuvant treatment in combination with chemotherapeutics or as a single agent following multi‐modality anthracycline‐based treatment.115. This evidence concerns the gene ERBB2 and breast carcinoma.